Anti vδ2 apc fire 750

Manufactured by BioLegend

The Anti-Vδ2-APC/Fire 750 is a fluorochrome-conjugated antibody that binds to the Vδ2 chain of the T cell receptor (TCR) on the surface of lymphoid cells. It is designed for use in flow cytometry applications to identify and quantify Vδ2-expressing T cells within a cell population.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd4 bv750, by BD (2 mentions) Anti vδ1 vioblue, by Miltenyi Biotec (2 mentions) Anti vβ11 apc, by Miltenyi Biotec (2 mentions) Zombie nir fixable viability kit, by BioLegend (1 mentions) Anti cd161 pe, by BioLegend (1 mentions) Anti cd8a bv510, by BioLegend (1 mentions) Anti cd56 bv605, by BioLegend (1 mentions) Aurora flow cytometer, by Cytek (1 mentions) Fcr blocking reagent, by Miltenyi Biotec (1 mentions) Aurora cytometer, by Cytek (1 mentions) Anti γδtcr fitc, by Thermo Fisher Scientific (1 mentions) Anti cd8a bv510 clone rpa t8, by BioLegend (1 mentions) Fc block, by Miltenyi Biotec (1 mentions) Zombie nir live dead exclusion dye, by BioLegend (1 mentions)

2 protocols using anti vδ2 apc fire 750

Comprehensive Characterization of T-cell Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols

Freshly thawed PBMCs (1.0–1.5×10⁶ cells) were stained with the Zombie NIR Fixable Viability Kit (BioLegend, 1:2000) for 15 minutes at room temperature. Cells were then stained with the following panel for 30 minutes on ice: FcR blocking reagent (Miltenyi Biotec, 1:50), anti-CD3-Alexa Fluor 532 (eBioscience, Clone: UCHT1, Cat: 58–0038-42, 1:50), anti-CD4-BV750 (BD Biosciences, Clone: SK3, Cat: 566356, 1:800), anti-CD8a-BV510 (BioLegend, 1:200), anti-CD56-BV605 (BioLegend, Clone: 5.1H11, Cat: 362537, 1:100), anti-γδTCR-FITC (eBioscience, Clone: B1.1, Cat: 11–9959-41, 1:50), anti-Vδ1-VioBlue (Miltenyi Biotec, Clone: REA173, Cat: 130–120-583, 1:50), anti-Vδ2-APC/Fire 750 (BioLegend, Clone: B6, Cat: 331419, 1:100), anti-CD161-PE (BioLegend, Clone: HP-3G10, Cat: 339938, 1:100), anti-Vα7.2-BV711 (BioLegend, Clone: 3C10, Cat: 351731, 1:100), anti-Vα24-Jα18-PE/Cy7 (BioLegend, Clone: 6B11, Cat: 342912, 1:100), and anti-Vβ11-APC (Miltenyi Biotec, Clone: REA559, Cat: 130–125-508, 1:50) antibodies. The cells were fixed by incubation with 2% PFA in PBS for 15 minutes at room temperature in the dark. Cells were acquired with an Aurora Flow Cytometer (Cytek). Data were analyzed with FlowJo.

Ogishi M., Yang R., Aytekin C., Langlais D., Bourgey M., Khan T., Ali F.A., Rahman M., Delmonte O.M., Chrabieh M., Zhang P., Gruber C., Pelham S.J., Spaan A.N., Rosain J., Lei W.T., Drutman S., Hellmann M.D., Callahan M.K., Adamow M., Wong P., Wolchok J.D., Rao G., Ma C.S., Nakajima Y., Yaguchi T., Chamoto K., Williams S.C., Emile J.F., Rozenberg F., Glickman M.S., Rapaport F., Kerner G., Allington G., Tezcan I., Cagdas D., Hosnut F.O., Dogu F., Ikinciogullari A., Rao V.K., Kainulainen L., Béziat V., Bustamante J., Vilarinho S., Lifton R.P., Boisson B., Abel L., Bogunovic D., Marr N., Notarangelo L.D., Tangye S.G., Honjo T., Gros P., Boisson-Dupuis S, & Casanova J.L. (2021). Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. Nature medicine, 27(9), 1646-1654.

+ Open protocol

+ Expand

Immunophenotyping of MAIT, iNKT, and γδ T cells

Cited 3 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

The immunophenotyping of MAIT, iNKT, and γδ T cells was performed as previously described^{8 (link)} on cryopreserved PBMCs from P1 prepared from a sample collected at the age of three years; and as previously described^{10 (link)} on cryopreserved PBMCs from P2 prepared from a sample collected at the age of six years. Both patients were receiving broad-spectrum antimycobacterial drugs. Briefly, staining was performed in the presence of Fcblock (Miltenyi Biotec), with Zombie-NIR live-dead exclusion dye (#423105, BioLegend), anti-CD3-Alexa532 (Clone UCHT1, # 58-0038-42, Thermo Fisher Scientific), anti-γδTCR-FITC (#11-9959-42, Thermo Fisher Scientific), anti-Vδ2-APC-Fire750 (#331420, BioLegend), anti-CD56-BV605 (clone 5.1H11, #362538, BioLegend), anti-CD4-BV750 (#5663656, BD Biosciences), anti-CD8a-BV510 (clone RPA-T8, #301047, BioLegend), anti-Vα7.2-BV711 (clone 3C10, #351731, BioLegend), anti-Vα24-Jα18-PE-Cy7 (clone 6B11, #342912, BioLegend), anti-Vδ1-Vioblue (#30-100-555, Miltenyi Biotec), anti-CD161-PE (clone HP-3G10, #339938, BioLegend) and anti-Vβ11-APC (Miltenyi Biotec) antibodies. Cells were analyzed with an Aurora cytometer (Cytek). The gating strategy for MAIT cells, iNKT cells, γδ1⁺ T cells, and γδ2⁺ T cells has been described elsewhere^{8 (link),69 (link)}.

Rosain J., Neehus A.L., Manry J., Yang R., Le Pen J., Daher W., Liu Z., Chan Y.H., Tahuil N., Türel Ö., Bourgey M., Ogishi M., Doisne J.M., Izquierdo H.M., Shirasaki T., Le Voyer T., Guérin A., Bastard P., Moncada-Velez M., Han J.E., Khan T., Rapaport F., Hong S.H., Cheung A., Haake K., Mindt B.C., Perez L., Philippot Q., Lee D., Zhang P., Rinchai D., Al Ali F., Ata M.M., Rahman M., Peel J.N., Heissel S., Molina H., Kendir-Demirkol Y., Bailey R., Zhao S., Bohlen J., Mancini M., Seeleuthner Y., Roelens M., Lorenzo L., Soudée C., Paz M.E., Gonzalez M.L., Jeljeli M., Soulier J., Romana S., L’Honneur A.S., Materna M., Martínez-Barricarte R., Pochon M., Oleaga-Quintas C., Michev A., Migaud M., Lévy R., Alyanakian M.A., Rozenberg F., Croft C.A., Vogt G., Emile J.F., Kremer L., Ma C.S., Fritz J.H., Lemon S.M., Spaan A.N., Manel N., Abel L., MacDonald M.R., Boisson-Dupuis S., Marr N., Tangye S.G., Di Santo J.P., Zhang Q., Zhang S.Y., Rice C.M., Béziat V., Lachmann N., Langlais D., Casanova J.L., Gros P, & Bustamante J. (2023). Human IRF1 governs macrophagic IFN-γ immunity to mycobacteria. Cell, 186(3), 621-645.e33.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!